The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -10,413,205 |
| Stock-based compensation expense | 5,290,329 |
| Issuance of common stock for services | 840,000 |
| Prepaid expenses | -3,183 |
| Trade accounts payable and accrued liabilities | -50,767 |
| Due to related parties | 224,802 |
| Accrued compensation - officer | 417,470 |
| Net cash used in operating activities | -3,688,188 |
| Repayment from officer | 155,518 |
| Proceeds from sale of common stock, related party | 3,000,000 |
| Net proceeds from sale of common stock | 6,553,209 |
| Net cash provided by financing activities | 9,708,727 |
| Net change in cash | 6,020,539 |
| Cash, beginning of year | 1,266,131 |
| Cash, end of year | 7,286,670 |
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)